See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

  • All
  • AAN
  • ESPID
  • APCCMI
  • ASCP
  • ASM Microbe
  • AVG and IMRP
  • CROI
  • ESCMID
  • GSA
  • IAS
  • IDWeek
  • ISIRV
  • NACFC
  • SCCM
  • All
  • 2024
  • 2025
  • 2026
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Gram-negative infection
  • Respiratory Syncytial Virus (RSV)
  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • S-337395
  • S-892216
  • Xeruborbactam
  • All
  • Oral presentation
  • Poster presentation

You Are Viewing Presentations

ESCMID 2026
Cefiderocol

Real-world cefiderocol outcomes in the treatment of Stenotrophomonas spp. infections: data from the PROVE study

View/Download Presentation
IDWeek 2024
Cefiderocol

Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: results of the PROVE chart review study

View/Download Presentation
ESCMID 2026
Cefiderocol

Real-world efficacy of cefiderocol for treatment of infections caused by metallo-beta-lactamase-producing enterobacterales in Spain

View/Download Presentation
AVG and IMRP 2025
Ensitrelvir

Real-world impact of early outpatient COVID-19 antiviral treatment on post-COVID-19 condition: the ANCHOR-01 study

View/Download Presentation
IDWeek 2024
Ensitrelvir

Real-world safety and effectiveness of ensitrelvir in COVID-19 patients with risk factor: a post-marketing surveillance in Japan

View/Download Presentation
ISIRV 2025
S-337395

S-337395, a novel L-protein inhibitor of respiratory syncytial virus demonstrates dose-dependent antiviral activity in a human challenge study

View/Download Presentation

You Are Viewing Congress Locations